Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Improvement on 6-point.. 33% Improvement Relative Risk Dound et al. Curcumin for COVID-19 RCT EARLY TREATMENT Is early treatment with curcumin+combined treatments beneficial for COVID-19? RCT 200 patients in India Improved 7-point scale results with curcumin+combined treatments (p=0.0001) Dound et al., J. Clinical Trials, S3:004 Favors curcumin Favors control
A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of SARS-COV-2 Infection (COVID-19)
Dound et al., Journal of Clinical Trials, S3:004
Dound et al., A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of.., Journal of Clinical Trials, S3:004
Nov 2020   Source   PDF  
  All Studies   Meta
RCT 200 COVID-19 positive patients in India, 100 treated with Curcumin, Vitamin C, Vitamin K2-7, and L-Selenomethionine, showing faster recovery with treatment. This study is excluded in the after exclusion results of meta analysis: potential randomization failure.
relative improvement on 6-point scale, 33.3% better, RR 0.67, p < 0.001, treatment 100, control 100.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dound et al., 16 Nov 2020, Randomized Controlled Trial, India, peer-reviewed, 5 authors, this trial uses multiple treatments in the treatment arm (combined with vitamin C, vitamin K2-7, and l-selenomethionine) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: OPEN ACCESS Freely available online Journal of Clinical Trials Research Article A Randomized, Comparative Clinical Study to Evaluate the Activity of Curvic TM Formulation for Management of SARS-COV-2 Infection (COVID-19) Yogesh Arun Dound1*, Sagar Mandlik5, Shrikant Suryavanshi2, Rajesh Sehgal3, Ajay Naik4 Department of Research & Development, Shreepad Shree Vallabh SSV Phytopharmaceuticals, C OO, Particle L ife Sciences Pvt. L td, Mumbai, 2 Maharashtra, India; Consulting Physician,Nashik, Maharashtra, India; 3 Department of Research & Development, Pharma Instinct, Noida, 5 Uttar Pradesh, India; 4 Administration, Rukmini Enterprises, Mumbai, Maharashtra, India; Chest Physician, Radiant Plus Hospital, Nashik, Maharashtra, India 1 ABSTRACT COVID-19 outbreak has put forward a huge challenge in front of researchers across the globe. Non availability of any vaccine or drug has worsened the situation and it has become a worst pandemic of modern times. Keeping scientific rationale and results of in silico studies, Researchers at Shreepad Shree Vallabh SSV Phytopharmaceuticals (SSV) have developed formulation containing natural ingredients viz Curcumin, Vitamin C, Vitamin K2-7, Selenomethionine and Zinc. Objective: To evaluate role of Curvic TM in the management of COVID-19 and its tolerability in comparison with standard treatment available from Ministry of Health and Family Welfare (MOHFW). Study design and methodology: In a randomized, two arm, comparative study, COVID-19 positive patients (n=200) were enrolled during the month of August and September 2020 from Radiant Plus Hospital, Nashik, Maharashtra, India. The enrolled patients were administered either Curvic TM 500 mg tablets twice daily or given standard treatment protocol designed by MOHFW for 10 days. The patients were evaluated for decrease in oral temperature; SpO2 and VAS score for cough and respiratory distress. The underlying mechanism was assessed by evaluating markers such as Interleukin-6, Homocysteine, D-dimer, Ferritin and C Reactive Protein. Results: In the Curvic TM group, within two days, temperature reduced considerably to afebrile level in all the subjects and remained afebrile till end of study. While in the standard treatment group, temperature reduced to afebrile stage in all the subjects by 4 days and there after remained afebrile till end of study. The elevated levels of serum Interleukin-6, Homocysteine, Di-dimer, Ferritin and C-Reactive Protein at baseline dropped considerably within normal limits within 10 days in the Curvic TM group in comparison to standard treatment group. Conclusion: Curvic TM has shown for the first time to be useful in management of COVID-19 positive patients along with improvement in the immunity, within 48 hours of starting treatment. Curvic TM was well tolerated without any side effects in any of the patients treated. Keywords: Curcumin; COVID-19; IL-6; Homocysteine; SARS-CoV
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop